CARGO Therapeutics downgraded by Chardan Capital Markets
$CRGX
Chardan Capital Markets downgraded CARGO Therapeutics from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2025 | Buy → Neutral | Chardan Capital Markets | |
| 1/30/2025 | $32.00 → $3.00 | Buy → Hold | Jefferies |
| 1/30/2025 | $34.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 1/30/2025 | Outperform → Mkt Perform | William Blair | |
| 1/30/2025 | Overweight → Underweight | Analyst | |
| 1/30/2025 | $32.00 → $7.00 | Buy → Hold | Truist |
| 1/30/2025 | Buy → Neutral | H.C. Wainwright | |
| 11/26/2024 | Outperform | William Blair |
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 - - Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination - SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel). The Company's Board of Directors has made the decis
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to implement a workforce reduction of approximately 50%.Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025. SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients, today announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBC
- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023, CARGO's tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 - - CARGO announces novel allogeneic platform based on a universal allogeneic-enabling vector intended to be paired with any new or existing CAR vector to create an allogeneic CAR T-cell therapy while leveraging existing autologous drug product processes - SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage bi
Chardan Capital Markets downgraded CARGO Therapeutics from Buy to Neutral
Jefferies downgraded CARGO Therapeutics from Buy to Hold and set a new price target of $3.00 from $32.00 previously
Piper Sandler downgraded CARGO Therapeutics from Overweight to Neutral and set a new price target of $4.00 from $34.00 previously
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
SCHEDULE 13G - CARGO Therapeutics, Inc. (0001966494) (Subject)
SCHEDULE 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)
SCHEDULE 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)
SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)
SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)
SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1'25 with Phase 1 initiation planned for 2025 - - Anup Radhakrishnan, CFO of CARGO Therapeutics, appointed as COO and CFO - SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided a
– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. "Jane's appointment exemplifies CARGO's ongoing commitment to strong corporate g
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ